13th Oct 2015 06:57
LONDON (Alliance News) - Hutchison China MediTech Ltd said Tuesday that its research and development subsidiary, Hutchison MediPharm Ltd, together with AstraZeneca PLC, has completed enrolment in a phase II study of savolitinib.
The phase II study is to evaluate the efficacy and safety of savolitinib in papillary renal cell carcinoma, a form of kidney cancer.
A total of 90 patients have been enrolled in the study. Interim data from the trial is expected to be published at the American Society of Clinical Oncology meeting in 2016, Hutchison China MediTech said.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
AstrazenecaHutchmed